Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:15:52.195Z.
Calculation as of: 2026-10-06T14:15:52.195Z.
Quote observation: 2026-10-06T14:15:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e18e4937bb179ad65bb801f5f057f36d78bd2e4af2c39ec5cecdad017acf428
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
BriaCell Therapeutics Corp.
Market Cap
$35.58M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$33.24M
Price/FCF Ratio
N/A
TTM Avg
507.99
3Y Avg
507.99
5Y Avg
507.99
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | $35.58M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $35.82M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.75M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $36.38M | N/A | 2.50 | 3.99 | 20.14 |
| Accuray Incorporated (ARAY)vs › | $36.59M | N/A | 8.65 | 28.12 | 30.77 |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.01M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.73M | N/A | N/A | N/A | N/A |
| HeartBeam, Inc. (BEAT)vs › | $33.53M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $33.24M | N/A | 507.99 | 507.99 | 507.99 |
| Aligos Therapeutics, Inc. (ALGS)vs › | $32.86M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
